ESPR

Esperion Therapeutics Inc.

Price

return (12m)

0.00%

p/e

-107.57

p/bv

-2.59

DIVIDEND YIELD

0.00%

ESPR price

Esperion Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ESPR

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals ESPR

Valuation

P/E

-107.57

Sector -4.25

Industry -4.25

P/BV

-2.59

Sector 2.02

Industry 2.02

P/Revenue (PSR)

1.91

Sector -4.24

Industry -4.24

EV/EBITDA

-148,636,889.00

Sector -61,637,555.16

Industry -61,637,555.16

EV/EBIT

-147,811,128.50

Sector -37,101,806.96

Industry -37,101,806.96

P/EBITDA

10.04

Sector -4.42

Industry -4.42

P/EBIT

10.05

Sector -4.46

Industry -4.46

P/Total Assets

1.73

Sector 1.44

Industry 1.44

P/Ativo Circ. Liq.

-2,566,495.18

Sector -11,369,656.32

Industry -11,369,656.32

P/Cap.Giro

5,016,844.75

Sector -10,584,388.41

Industry -10,584,388.41

EPS

-0.03

Sector -2.26

Industry -2.26

BVPS

-1.23

Sector 1.89

Industry 1.89

Efficiency

Gross Margin

68.38%

Sector 36.04%

Industry 36.04%

EBITDA Margin

-6.70%

Sector -16,822.56%

Industry -16,822.56%

EBIT Margin

-6.74%

Sector -4,256,846.44%

Industry -4,256,846.44%

Operating Margin

18.12%

Sector -39.46%

Industry -39.46%

Net Profit Margins

-1.77%

Sector -40.60%

Industry -40.60%

Giro Ativos

0.17

Sector 0.03

Industry 0.03

Profitability

ROE

2.41%

Sector -67.67%

Industry -67.67%

ROA

-1.60%

Sector -67.17%

Industry -67.17%

ROIC

-18.91%

Sector -2,910.52%

Industry -2,910.52%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

1.53

Sector 2.90

Industry 2.90

Dívida Líquida/EBITDA

-17.49

Sector -20.78

Industry -20.78

Dívida Líquida/EBIT

-17.39

Sector -3.57

Industry -3.57

Dívida Líquida/Patrimônio

-0.30

Sector -1.11

Industry -1.11

Dívida Bruta/Patrimônio

-0.81

Sector 0.00

Industry 0.00

Equity/Assets

-0.67

Sector 0.41

Industry 0.41

Liabilities/Assets

1.67

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

39.76%

Sector -

Industry -

5Y Earnings CAGR

-51.24%

Sector -

Industry -

Fundamentals ESPR

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
ESPR	-107.57	-2.59	2.41%	0.00%	$798.18 T	-1.77%
JNJ	30.06	7.44	24.76%	1.99%	$632.34 B	21.48%
PFE	18.39	1.52	8.29%	7.11%	$137.74 B	11.83%
ABBV	126.05	-69.30	-54.98%	2.60%	$458.19 B	5.79%
NVO	11.83	7.14	60.40%	3.68%	$224.33 B	37.15%
MRK	35.53	6.91	19.45%	2.62%	$317.48 B	13.59%
AZN	25.14	5.51	21.93%	1.90%	$261.15 B	17.19%
GILD	17.54	6.90	39.33%	2.47%	$161.64 B	30.99%
BMY	17.03	6.16	36.19%	4.11%	$123.88 B	15.01%
ZTS	12.10	9.90	81.75%	2.72%	$31.99 B	27.79%
REGN	15.66	2.20	14.08%	0.55%	$69.27 B	29.65%
HALO	27.62	43.86	158.82%	0.00%	$9.63 B	23.13%
AMGN	26.05	22.11	84.87%	2.60%	$203.18 B	20.96%
MCK	21.66	-123.68	-570.98%	0.39%	$103.15 B	1.18%
VRTX	28.35	6.35	22.41%	0.00%	$122.99 B	35.51%
CAH	34.90	-20.31	-58.20%	0.89%	$54.27 B	0.62%
HRMY	14.10	2.26	16.00%	0.00%	$2.05 B	16.20%
BIIB	21.68	1.59	7.36%	0.00%	$29.75 B	13.81%
MEDP	34.42	38.99	113.29%	0.00%	$16.92 B	17.67%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ESPR Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Esperion Therapeutics

Esperion Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

18 years

Founded: 2008

2013

Time since IPO - 13 years

193

Employees

Esperion Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $798.18 trillion, with shareholders equity totaling $-307.93 million.

The company employs approximately 193 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Esperion Therapeutics Inc. reported $418.25 million in revenue, generating net income of $-7.42 million.

Key financial metrics include a P/E ratio of -107.57, a price-to-book (P/B) ratio of -2.59, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ESPR.

Market cap

$798.18 trillion

Net worth

$-307.93 million

$-307,930,000.00

Assets

$462.53 million

$462,530,000.00

Total Shares Outstanding

251.00 million

251,000,000

Average Daily Trading Volume

$17.10 million

$17,099,834.00

Sector

Health Care

Industry

Biotechnology

ESPR

ESPR revenue and profits

Financial Results ESPR

DRAG THE FRAME TO SEE MORE DATA

ESPR cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

JNJ - Johnson & Johnson

$262.71 60,01% (12M)

P/E

30.06

1.99%

ROE

24.76%

P/BV

7.44

AZN - AstraZeneca

$168.59 19,41% (12M)

P/E

25.14

1.90%

ROE

21.93%

P/BV

5.51

ABBV - AbbVie

$258.87 41,59% (12M)

P/E

126.05

2.60%

ROE

-54.98%

P/BV

-69.30

PFE - Pfizer

$24.63 6,30% (12M)

P/E

18.39

7.11%

ROE

8.29%

P/BV

1.52

AMGN - Amgen

$376.27 26,40% (12M)

P/E

26.05

2.60%

ROE

84.87%

P/BV

22.11

GILD - Gilead Sciences

$130.15 14,88% (12M)

P/E

17.54

2.47%

ROE

39.33%

P/BV

6.90

REGN - Regeneron Pharmaceuticals

$666.10 19,89% (12M)

P/E

15.66

0.55%

ROE

14.08%

P/BV

2.20

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

JNJ - Johnson & Johnson

$262.71 60,01% (12 M)

P/L

30.06

1.99%

ROE

24.76%

P/VP

7.44

AZN - AstraZeneca

$168.59 19,41% (12 M)

P/L

25.14

1.90%

ROE

21.93%

P/VP

5.51

ABBV - AbbVie

$258.87 41,59% (12 M)

P/L

126.05

2.60%

ROE

-54.98%

P/VP

-69.30

PFE - Pfizer

$24.63 6,30% (12 M)

P/L

18.39

7.11%

ROE

8.29%

P/VP

1.52

AMGN - Amgen

$376.27 26,40% (12 M)

P/L

26.05

2.60%

ROE

84.87%

P/VP

22.11

GILD - Gilead Sciences

$130.15 14,88% (12 M)

P/L

17.54

2.47%

ROE

39.33%

P/VP

6.90

REGN - Regeneron Pharmaceuticals

$666.10 19,89% (12 M)

P/L

15.66

0.55%

ROE

14.08%

P/VP

2.20

Frequently Asked Questions

What is the price of Esperion Therapeutics (ESPR) today?

A cotação de Esperion Therapeutics (ESPR) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Esperion Therapeutics (ESPR) iniciou o ano negociando na casa dos US$ 3.70 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Esperion Therapeutics (ESPR) e dados de ações do Ibovespa e mercados internacionais.

Quando Esperion Therapeutics (ESPR) paga dividendos?

Esperion Therapeutics (ESPR) não distribuiu dividendos no último ano.

Is Esperion Therapeutics (ESPR) a good investment?

Atualmente, Esperion Therapeutics (ESPR) está cotada a US$ 0.00, com um P/L de -107.57, representando um desvio de -3,157% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Esperion Therapeutics (ESPR) stock?

Investir em ações de Esperion Therapeutics (ESPR) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Esperion Therapeutics (ESPR) yield today?

A rentabilidade de Esperion Therapeutics (ESPR) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Esperion Therapeutics (ESPR) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ESPR

Esperion Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment ESPR

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Esperion Therapeutics

Esperion Therapeutics Inc.

United States

18 years

2013

193

PROFIT X PRICE ESPR

Financial Results ESPR

ESPR cash flow

Asset, Revenue and Profit Growth - ESPR

ESPR balance sheet

BFRA - Biofrontera

JNJ - Johnson & Johnson

AZN - AstraZeneca

ABBV - AbbVie

PFE - Pfizer

AMGN - Amgen

GILD - Gilead Sciences

REGN - Regeneron Pharmaceuticals

BFRA - Biofrontera

JNJ - Johnson & Johnson

AZN - AstraZeneca

ABBV - AbbVie

PFE - Pfizer

AMGN - Amgen

GILD - Gilead Sciences

REGN - Regeneron Pharmaceuticals

Frequently Asked Questions